Companies › Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
1 active drug program in 4 registered trials: 2 Phase 3, 2 Phase 2; Metabolic and endocrine; next expected readout Sep 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| aleniglipron GLP-1 receptor agonist | GLP1R | Phase 3 | Obesity; Obesity, Overweight, or Chronic Weight Management; Obese | Sep 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07169942 | aleniglipron | Phase 2 | Obesity, Overweight, or Chronic Weight Management | Metabolic and endocrine | Sep 2026 |
| NCT07400588 | aleniglipron | Phase 2 | Obese | Metabolic and endocrine | Sep 2026 |
| NCT07654374 | aleniglipron | Phase 3 | Obesity | Metabolic and endocrine | Sep 2028 |
| NCT07654361 | aleniglipron | Phase 3 | Obesity | Metabolic and endocrine | Sep 2028 |
Chendu DIAO Pharmaceutical Group Beijing QL Biopharmaceutical Beijing Dongfang Biotech Kailera BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.